Published in Clin Exp Nephrol on February 27, 2015
Pathophysiology of copeptin in kidney disease and hypertension. Clin Hypertens (2017) 0.75
Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis (2009) 18.60
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem (2005) 3.55
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest (1973) 2.64
Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int (2010) 2.48
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol (2012) 1.78
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation (2009) 1.69
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 1.67
Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab (2008) 1.61
Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. Am J Physiol Regul Integr Comp Physiol (2013) 1.56
Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab (2007) 1.39
Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.32
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.16
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2011) 1.12
Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) (2009) 1.11
Angiotensin type 1a receptors in the subfornical organ are required for deoxycorticosterone acetate-salt hypertension. Hypertension (2012) 1.03
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis (2012) 1.01
Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol (1998) 1.00
The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol (1994) 0.99
A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 0.94
Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem (1999) 0.90
Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol (2012) 0.86
Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab (2014) 0.85
Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol (2014) 0.85
Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant Proc (2010) 0.83
Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. Am J Physiol Renal Physiol (2012) 0.82
Novel prediction model of renal function after nephrectomy from automated renal volumetry with preoperative multidetector computed tomography (MDCT). Clin Exp Nephrol (2015) 0.90
In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease". Clin Exp Nephrol (2015) 0.75
Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? Kidney Int (2015) 0.75